Alexandria Hammond
Stock Analyst at B of A Securities
(2.74)
# 1,580
Out of 5,182 analysts
15
Total ratings
72.73%
Success rate
14.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $512.39 | +3.24% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $198.71 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $111.90 | +20.64% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $751.57 | +53.01% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $27.00 | -7.41% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $50.73 | -21.15% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $883.96 | +13.13% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $227.50 | -16.48% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $130.40 | -15.64% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $58.71 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $184.38 | - | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $512.39
Upside: +3.24%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $198.71
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $111.90
Upside: +20.64%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $751.57
Upside: +53.01%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $27.00
Upside: -7.41%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $50.73
Upside: -21.15%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $883.96
Upside: +13.13%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $227.50
Upside: -16.48%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $130.40
Upside: -15.64%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $58.71
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $184.38
Upside: -